Needham maintains Nkarta at Buy, keeps price target at $11

Needham reaffirmed its Buy rating and $11 price target for Nkarta, suggesting a 535.8% upside from its Nov 6 close of $1.73.

Original reporting
Published Nov 9, 2026, 4:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 5:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Needham maintains Nkarta at Buy, keeps price target at $11 — source image
Decision brief

The 30-second read

Low
01

Why it matters

The rating maintenance does not introduce new information beyond the price target, offering limited trading impetus.

02

Market read

The article provides a modest update on Nkarta's valuation but lacks a fresh catalyst, resulting in low trading relevance.

03

What to watch

Potential upcoming clinical trial data could materially change the outlook, which is not reflected in the current rating.

Relevance 4/10Novelty 3/10Timing: today

Background

Needham's analyst coverage of Nkarta includes a Buy rating and a $11 price target, implying a 535.8% upside from the recent close.

Market effects

Reinforces bullish sentiment for the biotech sector but limited to Nkarta.

Minimal impact on broader US markets.

Low

Counterpoint

Investors may view the unchanged rating as a sign of stagnation and could wait for a catalyst before buying.

Key entities

  • Nkarta

    Biotech firm focused on cellular immunotherapies.

  • Needham

    Equity research analyst firm providing the rating.

Related articles

$NKTXHighAI 8/10

Nkarta reports safety data for autoimmune cell therapy NKX019

Nkarta Inc. (NKTX) presented safety data for NKX019, its CD19-directed CAR NK cell therapy, in a clinical trial for autoimmune diseases. The data, from 40 patients, showed no serious adverse events. Treatment-emergent adverse events occurred in 85% of patients, with 35% experiencing grade 3 or higher events, primarily hematologic. NKX019 is manufactured from donor-derived NK cells.

$NKTXMedAI 8/10

Nkarta Reports Initial NKX019 Clinical Responses in Myositis and Systemic Sclerosis Trials

Nkarta (NKTX) presented early clinical data for NKX019, showing positive responses in myositis and systemic sclerosis trials. 83% of myositis patients and 86% of systemic sclerosis patients responded to treatment. Safety data from 40 patients showed no serious adverse events. Nkarta plans to evaluate a higher dose and engage with the FDA for potential registration pathways.

$NKTXMedAI 9/10

Nkarta reports early trial data for autoimmune cell therapy

Nkarta Inc. (NKTX) presented early trial data for NKX019, an experimental cell therapy for autoimmune diseases. In trials with 40 patients, 83% of myositis patients and 86% of systemic sclerosis patients showed significant responses. No serious adverse events were reported. Nkarta plans to evaluate higher doses and discuss potential registration pathways with the FDA.

$NKTXLow

Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026

Nkarta, Inc. (NKTX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026 SOUTH SAN FRANCISCO, Calif., November 6, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineer